EVOQ REMEDIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.35 INR | -2.09% |
|
-4.10% | -36.61% |
| 06-11 | Evoq Remedies Limited announced that it expects to receive INR 192.1 million in funding | CI |
| 05-27 | Evoq Remedies Limited Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
| Sales 2022 | 168M 2.01M 2.75M | Sales 2023 | 264M 3.16M 4.33M | Capitalization | 177M 2.11M 2.9M |
|---|---|---|---|---|---|
| Net income 2022 | 10M 120K 164K | Net income 2023 | 16M 191K 263K | EV / Sales 2022 | 2.13 x |
| Net Debt 2022 | 50.64M 606K 831K | Net Debt 2023 | 94.23M 1.13M 1.55M | EV / Sales 2023 | 1.03 x |
| P/E ratio 2022 |
20.7
x | P/E ratio 2023 |
10.9
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 78.44% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.09% | ||
| 1 week | -4.10% | ||
| Current month | -1.37% | ||
| 1 month | -4.59% | ||
| 3 months | -4.59% | ||
| 6 months | -24.05% | ||
| Current year | -36.61% |
1 week
8.86
9.80
1 month
8.6210.80
Current year
8.5019.44
1 year
8.5019.44
3 years
8.5025.00
5 years
8.5025.00
10 years
8.5025.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 42 | 02-02 | |
Yogesh M. Rajput
DFI | Director of Finance/CFO | - | 22-02-11 |
| Compliance Officer | 36 | 02-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 67 | 23-09-10 | |
| Director/Board Member | 32 | 22-02-02 | |
| Director/Board Member | 30 | 22-02-02 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-20 | 9.35 | -2.09% | 16 000 |
| 24-06-19 | 9.55 | +0.42% | 12,000 |
| 24-06-18 | 9.51 | +2.48% | 36,000 |
| 24-06-14 | 9.28 | -4.82% | 44,000 |
| 24-06-13 | 9.75 | +4.28% | 20,000 |
Delayed Quote Bombay S.E., June 20, 2024 at 06:00 am
More quotes
EVOQ Remedies Limited is an India-based company, which is a manufacturer and supplier of pharmaceutical products. The Company is engaged in the pharmaceutical business involving marketing, trading, and distribution of a range of pharmaceutical formulation products, such as antibiotic drugs, anti-malarial drugs, anti-allergic and cold drugs, analgesic/antipyretic and anti-inflammatory drugs, dermatology products, cerebral activator drugs, neurological drugs, gastrointestinal drugs, steroids, gynecology drugs, calcium, multivitamins, antioxidants, and injections. It offers a range of pharmaceutical formulation products, of which around 120 products are marketed by the Company under its own brand name. It also deals in the trading of active pharmaceutical ingredients (APIs). Its products include Abacavir Sulphate, Acetazolamide, Acyclovir, Adefovir Dipivoxil Allylestrenole, Alpha Beta Arteether, Alpha Lipoic Acid, Alprazolam , Amoxycillin Trihydrate, Ampicillin Trihydrate, and more.
Sector
Pharmaceuticals
Calendar
2024-11-05
- Q2 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -36.61% | 1.56M | |
| +52.93% | 803B | |
| +41.27% | 631B | |
| -7.08% | 351B | |
| +17.40% | 324B | |
| +10.58% | 303B | |
| +16.77% | 243B | |
| +2.13% | 228B | |
| +10.23% | 217B | |
| +6.24% | 164B |
- Stock Market
- Equities
- 543500 Stock
